At Kernal Bio, we engineer human cells inside the body using selective mRNA-LNP technology to treat cancer and autoimmune diseases. Our AI-designed mRNAs, delivered via antibody-decorated lipid nanoparticles (LNPs), ensure precise targeting and minimize off-target effects. Our KR-402 program focuses on hematological malignancies and autoimmune disorders, achieving >90% in vivo delivery efficiency with T-cell-targeted LNPs. The KR-335 program, targeting solid tumors resistant to standard immunotherapies, shows a 100x therapeutic index with strong efficacy and tolerability in preclinical models, including mice and non-human primates. With roots at MIT, Harvard, Merck, and BMS, our management team has spearheaded the development of three FDA-approved therapies and holds over 120 patents. Based in Cambridge, MA, and backed by Hummingbird Ventures, Amgen Ventures, and NASA, Kernal Bio is revolutionizing mRNA therapeutics by leveraging AI to deliver precision treatments within the body.
Kernal is dedicated to providing a diverse work environment and is committed to equal employment opportunities for all its employees and qualified applicants. We do not discriminate in employment practices for reasons of race, color, national origin, age, gender, sexual orientation, marital or veteran status, religion, disability, or any other legally protected status. Kernal will make reasonable accommodations for qualified individuals with known disabilities by applicable law.